Why VCs Are Funding Synthetic Biology Startups
The Venture Capital Podcast with Fexingo: VCs, Term Sheets, and Startup Investing · 2026-06-21 · 8 min
Episode notes
In this episode of The Venture Capital Podcast with Fexingo, Lucas and Luna explore the mechanics behind a new wave of VC funding in synthetic biology. They anchor on the recent 10.1% weekly jump in ARKG, Cathie Wood's genomics ETF, and the $2.8 billion Series C raised by Ginkgo Bioworks. Lucas breaks down why top firms like Founders Fund and Andreessen Horowitz are placing big bets on syn-bio, comparing the current moment to the early days of cloud computing. Luna challenges whether the hype is sustainable, pointing to regulatory hurdles and the long timelines for product commercialization. Together, they drill into one specific deal: the $450 million round for a startup engineering yeast to produce sustainable jet fuel. Expect concrete numbers, a clear thesis, and one actionable takeaway for founders considering this space. #SyntheticBiology #VentureCapital #GinkgoBioworks #ARKG #FoundersFund #AndreessenHorowitz #Biotech #StartupInvesting #Genomics #SustainableAviationFuel #CathieWood #SeriesC #BusinessPodcast #FexingoBusiness #Technology #Bioengineering #DealFlow #DeepTech Keep every episode free: buymeacoffee.com/fexingo